WP
RAPT

Woodline Partners’s RAPT Therapeutics RAPT Stock Holding History

Woodline Partners’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,624
Closed -$476K – 982
2024
Q3 		$476K Buy
29,624
+8,876
+43% +$180K ﹤0.01% 539
2024
Q2 		$506K Sell
20,748
-19,454
-48% -$899K ﹤0.01% 500
2024
Q1 		$2.89M Buy
40,202
+15,052
+60% +$2.09M 0.03% 407
2023
Q4 		$5M Buy
25,150
+18,900
+302% +$2.34M 0.05% 319
2023
Q3 		$831K Hold
6,250
– – 0.01% 461
2023
Q2 		$935K Buy
+6,250
New +$974K 0.01% 490
2023
Q1 		– Sell
-33,018
Closed -$5.23M – 757
2022
Q4 		$5.23M Sell
33,018
-118,043
-78% -$18.9M 0.07% 308
2022
Q3 		$29.1M Buy
151,061
+43,685
+41% +$8.26M 0.41% 61
2022
Q2 		$15.7M Buy
107,376
+62,571
+140% +$8.34M 0.24% 128
2022
Q1 		$7.88M Buy
+44,805
New +$8.46M 0.13% 196
2020
Q4 		– Sell
-8,413
Closed -$2.17M – 265
2020
Q3 		$2.17M Buy
+8,413
New +$1.87M 0.07% 161

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners's RAPT Position: Q4 2024 in Review

Woodline Partners sold out of RAPT Therapeutics (RAPT) in Q4 2024, closing a stake of 29,624 shares — an estimated $476K sold.

Woodline Partners first reported a position in RAPT in Q3 2020 and held it in 11 quarters. The position peaked at $29.1M in Q3 2022. 91 funds tracked by Wall St. Rank hold RAPT as of Q4 2024.

  • Woodline Partners reported no remaining RAPT Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 29,624 RAPT Therapeutics shares in Q4 2024, an estimated $476K.
  • Woodline Partners first reported a position in RAPT Therapeutics in Q3 2020 and held it in 11 quarters.
  • Woodline Partners's RAPT Therapeutics position peaked at $29.1M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.